Evidence of opportunistic infection with natalizumab Patients with relapsing-remitting MS treated with natalizumab have a high rate of John Cunningham virus (JCV) seroconversion. A study of 1,001 patients in Australia and Brazil found a durable positive seroconversion rate of 24.1% or 7.3% per year in initially JCV-negative patients. Seroconversion was more common in males than ...
News in brief: Virus seroconversion with natalizumab; Renal risk factor for stroke; Brain stimulation gets Budget funding
13 May 2021